BioStock: Cereno Scientific raises 95.3 million SEK
The recent IND FDA acceptance to initiate its phase II trial with CS1 in pulmonary arterial hypertension patients was a key milestone for Cereno Scientific. Last week, the company announced it was able to raise more than 95 MSEK through a TO1 warrant exercise, which gives the company even more assurance in the pursuit of its vision to develop better treatments for common and rare cardiovascular diseases.Read the article at biostock.se: https://www.biostock.se/en/2021/10/cereno-scientific-raises-95-3-million-sek/ This is a press release from BioStock - Connecting Innovation & Capital.